Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876796 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02876796 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 30 participants.
The verdict
NCT02876796, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.
Interventions
- DRUG Placebo
- DRUG GS-0976
- OTHER 1-13C acetate
- OTHER Fructose solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02876796
The ClinicalTrials.gov registry entry for NCT02876796 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02876796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02876796 about?
NCT02876796 is a clinical study titled "Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects". The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.
What is the current status of trial NCT02876796?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02876796?
The interventions under investigation include: Placebo (DRUG), GS-0976 (DRUG), 1-13C acetate (OTHER), Fructose solution (OTHER).
Who is sponsoring clinical trial NCT02876796?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.